GALE: Galena Biopharma, Inc. - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

Galena Biopharma, Inc.

NASDAQ:GALE

SummaryFactSheetFinancial
Notice
Stock data is unavailable or the company’s delisted.
Price
$6.70
Loss Chance
58.4%
1.70JITTA SCORE
n/a
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Related
Alexion Pharmaceuticals
NASDAQ:ALXN
6.89
$182.50
52.20%
Amgen
NASDAQ:AMGN
6.24
$336.45
37.82%
Arena Pharmaceuticals
NASDAQ:ARNA
0.01
$99.99
100.00%
Biogen
NASDAQ:BIIB
5.83
$204.53
18.84%
Celgene Corporation
NASDAQ:CELG
8.55
$108.24
17.72%
Jitta Factors
Growth Opportunity (0)
Recent Business Performance (30)
Financial Strength (0)
Return to Shareholders (0)
Competitive Advantage (0)
Jitta Signs
Recent Business PerformanceEarning decline 56.41% in the last year
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
1.70
n/a
2.19
147.21%
n/a
n/a
Biotechnology
6.24
37.82%
0.01
100.00%
5.83
18.84%
COMPANY DESCRIPTION
As of December 29, 2017, Galena Biopharma, Inc. was acquired by SELLAS Life Sciences Group AG, in a reverse merger transaction. Galena Biopharma, Inc., a biopharmaceutical company, develops hematology and oncology therapeutics that address unmet medical needs. The company develops GALE-401 (anagrelide controlled release), which completed Phase II clinical trial for the treatment of patients with myeloproliferative neoplasms to lower elevated platelet levels. It also develops NeuVax (nelipepimut-S), which is in Phase IIb clinical trial in combination with trastuzumab for HER2 1+ and 2+ node positive and high-risk node negative breast cancer patients; Phase II clinical trial in combination with trastuzumab for HER2 3+ breast cancer patients; Phase II clinical trial for women with ductal carcinoma in situ of the breast; and Phase II clinical trial for patients with gastric cancer. In addition, the company develops GALE-301 and GALE-302 for ovarian, endometrial, and breast cancers. It has strategic development and commercialization partnership with Dr. Reddy’s Laboratories Ltd. for NeuVax in breast and gastric cancers. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in San Ramon, California.
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.